TOKYO—The antiviral drug remdesivir appeared to have an effect in American cruise passengers treated for the novel coronavirus in Japan, although data are limited, according to a doctor sent to Tokyo by the U.S. government. Rear Adm. Richard Childs, an assistant surgeon general and lung specialist at the National Institutes of Health, said 14 Americans who contracted the virus on the Diamond Princess cruise ship and were treated at Japanese hospitals received the experimental drug from Gilead Sciences Inc. Those 14 were “critically ill people and their average age is 75,” he said. “Many of them were probably going to die in a short amount of time, and two weeks later nobody has died and more than half of them have recovered. It’s just absolutely amazing.” But he cautioned, “It’s going to take us a while to figure out what the impact of the drug has been.” The drug is being tested in the U.S. and Asia by independent groups as well as Gilead, but no large-scale results are available. Japan is one of the places where remdesivir is set to be compared with a placebo, a trial design likely to offer a better sense of the drug’s efficacy. “There is a lot of work to do,” said Norio Ohmagari, head of infectious diseases at the National Center for Global Health and Medicine in Tokyo, who is leading the Japanese trial set to start this month. The cruise passengers probably had better odds than the average person their age. “They are not bedridden, they are high-performing older folk that maybe already have their next cruise planned,” Dr. Childs said. He said his experience in Japan offered lessons for the U.S., which now has more than 1,700 infected people, and suggested factors beyond drug treatment that increase survival. One is making restoring lung function the priority—sometimes using an advanced form of life support that oxygenates the blood and pumps it back into the same vein from which it was extracted. “When everything hit the fan, the Japanese knew to focus on the lungs and make sure to get the right kind of support they need,” said Dr. Childs, clinical director at the NIH’s National Heart, Lung and Blood Institute. The Diamond Princess was put under two-week quarantine Feb. 5 after docking in Yokohama. In the following days, hundreds of passengers were diagnosed with the virus and taken by ambulance to Japanese hospitals. Ultimately more than 700 passengers and crew tested positive, and eight passengers have died—seven in Japan and one Australian who had returned home. Americans who tested negative returned home on evacuation flights that departed Feb. 17, but Dr. Childs said officials realized the mission wasn’t over because about 50 Americans were still hospitalized in Japan in isolation rooms. He arrived in Japan Feb. 19. As in other countries including China, doctors in Japan have been trying a variety of existing drugs, including some used to treat AIDS and influenza, as well as steroids to reduce inflammation. “Once we made it clear there was a possibility of getting remdesivir, most of them jumped at the opportunity,” Dr. Childs said of Japanese doctors. The American patients were scattered among hospitals in ones and twos. Dr. Childs turned to a former student, Takehito Igarashi, a Tokyo-based endocrinology surgeon, who told the U.S. team that getting the medical records would require faxing individual requests to each doctor. They also got health-ministry approval for an emergency shipment of the experimental drug. Dr. Childs set up a war room in the U.S. Embassy and studied X-rays, laboratory results and medical history of each patient before 14 Americans were selected to receive remdesivir. Three Japanese patients also qualified. “This particular situation with Japan absorbing a large number of international cases from the cruise ship was unique,” said Diana Brainard, Gilead’s senior vice president for HIV and emerging viral infections. In late February, the first patient received the drug, and Dr. Childs traveled to hospitals across the Tokyo region to meet doctors and patients’ families. Remdesivir is administered intra-venously once a day for 10 days, with a higher dose the first day. Dr. Childs said he noticed patients needed less support from a ventilator after getting the drug. All 17 patients who received remdesivir are alive, though five of the Americans remain critically ill. The situation “certainly has the feel that the drug was doing something. It’s almost impossible to prove it,” Dr. Childs said. Write to Suryatapa Bhattacharya at Suryatapa.Bhattacharya@wsj.com Correction Dr. Richard Childs arrived in Japan on Feb. 19 to help Americans who contracted the novel coronavirus. An earlier version of this article incorrectly implied he arrived on Feb. 16. (March 14, 2020)
带什么节奏？不要一来就给人戴帽子。待在美国的人哪个不希望这个药有效？
金银潭说的是有效，据说是对有些人很有效，有些人没效
全世界有谁不希望这个药有疗效的吗？又是哪个中国专家说这个没啥疗效？曹彬那里临床还没结束，中国专家认为这个药没什么效果结论从哪里来的
早期不是让在家扛着吗？等到可以住院了，不知道还来不来得及用药
看不了全文
上面不是说都是重症吗
TOKYO—The antiviral drug remdesivir appeared to have an effect in American cruise passengers treated for the novel coronavirus in Japan, although data are limited, according to a doctor sent to Tokyo by the U.S. government. Rear Adm. Richard Childs, an assistant surgeon general and lung specialist at the National Institutes of Health, said 14 Americans who contracted the virus on the Diamond Princess cruise ship and were treated at Japanese hospitals received the experimental drug from Gilead Sciences Inc. Those 14 were “critically ill people and their average age is 75,” he said. “Many of them were probably going to die in a short amount of time, and two weeks later nobody has died and more than half of them have recovered. It’s just absolutely amazing.” But he cautioned, “It’s going to take us a while to figure out what the impact of the drug has been.” The drug is being tested in the U.S. and Asia by independent groups as well as Gilead, but no large-scale results are available. Japan is one of the places where remdesivir is set to be compared with a placebo, a trial design likely to offer a better sense of the drug’s efficacy. “There is a lot of work to do,” said Norio Ohmagari, head of infectious diseases at the National Center for Global Health and Medicine in Tokyo, who is leading the Japanese trial set to start this month. The cruise passengers probably had better odds than the average person their age. “They are not bedridden, they are high-performing older folk that maybe already have their next cruise planned,” Dr. Childs said. He said his experience in Japan offered lessons for the U.S., which now has more than 1,700 infected people, and suggested factors beyond drug treatment that increase survival. One is making restoring lung function the priority—sometimes using an advanced form of life support that oxygenates the blood and pumps it back into the same vein from which it was extracted. “When everything hit the fan, the Japanese knew to focus on the lungs and make sure to get the right kind of support they need,” said Dr. Childs, clinical director at the NIH’s National Heart, Lung and Blood Institute. The Diamond Princess was put under two-week quarantine Feb. 5 after docking in Yokohama. In the following days, hundreds of passengers were diagnosed with the virus and taken by ambulance to Japanese hospitals. Ultimately more than 700 passengers and crew tested positive, and eight passengers have died—seven in Japan and one Australian who had returned home. Americans who tested negative returned home on evacuation flights that departed Feb. 17, but Dr. Childs said officials realized the mission wasn’t over because about 50 Americans were still hospitalized in Japan in isolation rooms. He arrived in Japan Feb. 19. As in other countries including China, doctors in Japan have been trying a variety of existing drugs, including some used to treat AIDS and influenza, as well as steroids to reduce inflammation. “Once we made it clear there was a possibility of getting remdesivir, most of them jumped at the opportunity,” Dr. Childs said of Japanese doctors. The American patients were scattered among hospitals in ones and twos. Dr. Childs turned to a former student, Takehito Igarashi, a Tokyo-based endocrinology surgeon, who told the U.S. team that getting the medical records would require faxing individual requests to each doctor. They also got health-ministry approval for an emergency shipment of the experimental drug. Dr. Childs set up a war room in the U.S. Embassy and studied X-rays, laboratory results and medical history of each patient before 14 Americans were selected to receive remdesivir. Three Japanese patients also qualified. “This particular situation with Japan absorbing a large number of international cases from the cruise ship was unique,” said Diana Brainard, Gilead’s senior vice president for HIV and emerging viral infections. In late February, the first patient received the drug, and Dr. Childs traveled to hospitals across the Tokyo region to meet doctors and patients’ families. Remdesivir is administered intra-venously once a day for 10 days, with a higher dose the first day. Dr. Childs said he noticed patients needed less support from a ventilator after getting the drug. All 17 patients who received remdesivir are alive, though five of the Americans remain critically ill. The situation “certainly has the feel that the drug was doing something. It’s almost impossible to prove it,” Dr. Childs said. Write to Suryatapa Bhattacharya at Suryatapa.Bhattacharya@wsj.com Correction Dr. Richard Childs arrived in Japan on Feb. 19 to help Americans who contracted the novel coronavirus. An earlier version of this article incorrectly implied he arrived on Feb. 16. (March 14, 2020)
用药的当然有效，对照组的当然没效，又没揭盲
Trial没招满人，搞的没法按计划结束，仿制药都已经做出来了，且拿去意大利当人情送了，服气呀
😂
自己国民强制加中药，对外还是舍不得